Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cell|November 3, 2009
PI3 kinase signals BCR-dependent mature B cell survivalLakshmi Srinivasan, Yoshiteru Sasaki, Dinis Pedro Calado, et al.EMBO Molecular Medicine|March 13, 2015
Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanismsAlex Pellerin, Karel Otero, Julie M Czerkowicz, et al.Science (New York, N.Y.)|November 18, 2006
Generation of gut-homing IgA-secreting B cells by intestinal dendritic cellsJ Rodrigo Mora, Makoto Iwata, Bertus Eksteen, et al.Proceedings of the National Academy of Sciences of the United States of America|March 25, 2026
Polypharmacology of S-1117, an Fc-fused IgG-selective degrading enzyme, for chronic treatment of autoantibody-mediated diseasesLiliana M Sanmarco, Alex Pellerin, Tobias Green, et al.Plos Biology|March 9, 2005
Basal immunoglobulin signaling actively maintains developmental stage in immature B cellsLina E Tze, Brian R Schram, Kong-Peng Lam, et al.Proceedings of the National Academy of Sciences of the United States of America|October 21, 2025
Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathologyAlexandra C Bayer, Liliana M Sanmarco, Alex Pellerin, et al.Journal of Medicinal Chemistry|July 23, 2020
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune DiseasesBin Ma, Tonika Bohnert, Kevin L Otipoby, et al.Bioorganic & Medicinal Chemistry|May 30, 2019
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screensBrian T Hopkins, Eris Bame, Noah Bell, et al.Journal of Medicinal Chemistry|November 4, 2021
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple SclerosisBrian T Hopkins, Eris Bame, Bekim Bajrami, et al.Immunohorizons|March 26, 2025
Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial dataJohannes F Scheid, Kiki Cunningham-Bussel, Nancy Kim, et al.Pageof 2